Your browser doesn't support javascript.
loading
Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.
Xiong, Zhaoping; Jeon, Minji; Allaway, Robert J; Kang, Jaewoo; Park, Donghyeon; Lee, Jinhyuk; Jeon, Hwisang; Ko, Miyoung; Jiang, Hualiang; Zheng, Mingyue; Tan, Aik Choon; Guo, Xindi; Dang, Kristen K; Tropsha, Alex; Hecht, Chana; Das, Tirtha K; Carlson, Heather A; Abagyan, Ruben; Guinney, Justin; Schlessinger, Avner; Cagan, Ross.
Afiliação
  • Xiong Z; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
  • Jeon M; Department of Computer Science and Engineering, Korea University, Seoul, Republic of Korea.
  • Allaway RJ; Sage Bionetworks, Seattle, Washington, United States of America.
  • Kang J; Department of Computer Science and Engineering, Korea University, Seoul, Republic of Korea.
  • Park D; Interdisciplinary Graduate Program in Bioinformatics, Korea University, Seoul, Republic of Korea.
  • Lee J; Department of Computer Science and Engineering, Korea University, Seoul, Republic of Korea.
  • Jeon H; Department of Computer Science and Engineering, Korea University, Seoul, Republic of Korea.
  • Ko M; Interdisciplinary Graduate Program in Bioinformatics, Korea University, Seoul, Republic of Korea.
  • Jiang H; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Zheng M; Department of Computer Science and Engineering, Korea University, Seoul, Republic of Korea.
  • Tan AC; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
  • Guo X; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Dang KK; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, United States of America.
  • Tropsha A; Sage Bionetworks, Seattle, Washington, United States of America.
  • Das TK; Sage Bionetworks, Seattle, Washington, United States of America.
  • Carlson HA; Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America.
  • Abagyan R; Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York City, New York, United States of America.
  • Guinney J; Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York City, New York, United States of America.
  • Schlessinger A; Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Cagan R; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, United States of America.
PLoS Comput Biol ; 17(9): e1009302, 2021 09.
Article em En | MEDLINE | ID: mdl-34520464
ABSTRACT
A continuing challenge in modern medicine is the identification of safer and more efficacious drugs. Precision therapeutics, which have one molecular target, have been long promised to be safer and more effective than traditional therapies. This approach has proven to be challenging for multiple reasons including lack of efficacy, rapidly acquired drug resistance, and narrow patient eligibility criteria. An alternative approach is the development of drugs that address the overall disease network by targeting multiple biological targets ('polypharmacology'). Rational development of these molecules will require improved methods for predicting single chemical structures that target multiple drug targets. To address this need, we developed the Multi-Targeting Drug DREAM Challenge, in which we challenged participants to predict single chemical entities that target pro-targets but avoid anti-targets for two unrelated diseases RET-based tumors and a common form of inherited Tauopathy. Here, we report the results of this DREAM Challenge and the development of two neural network-based machine learning approaches that were applied to the challenge of rational polypharmacology. Together, these platforms provide a potentially useful first step towards developing lead therapeutic compounds that address disease complexity through rational polypharmacology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tauopatias / Inibidores de Proteínas Quinases / Proteínas Proto-Oncogênicas c-ret / Desenvolvimento de Medicamentos / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: PLoS Comput Biol Assunto da revista: BIOLOGIA / INFORMATICA MEDICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tauopatias / Inibidores de Proteínas Quinases / Proteínas Proto-Oncogênicas c-ret / Desenvolvimento de Medicamentos / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: PLoS Comput Biol Assunto da revista: BIOLOGIA / INFORMATICA MEDICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China